Genfit announces the release of NASHnext
Genfit, in association with Labcorp, announced the launch of a noninvasive nonalcoholic steatohepatitis test for at-risk patients, according to a press release.
Using a novel, blood-based molecular biomarker test, NASHnext identifies NASH and significant fibrosis in patients with at least one metabolic risk factor. Researchers hope the widespread availability of this test will allow for clearer early diagnoses and aid in informed decision making to monitor or slow the progression of liver disease.
“NASH is a widespread yet underdiagnosed liver disease with very serious consequences including end-stage liver disease and cardiovascular events,” Brian Caveney, MD, chief medical ocer and president of Labcorp Diagnostics, said in the release. “NASHnext has the potential to substantially benet very large patient populations by providing people with essential information regarding their liver health.”
The test is offered exclusively in the U.S. and Canada through Labcorp.